Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75312

Title: Review EGFR-TKIs administration to non-small-cell lung cancer patients undergoing hemodialysis

Provenance and peer review: Unsolicited manuscript; externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05524527
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Taiwan

Manuscript submission date: 2022-01-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-09 02:55

Reviewer performed review: 2022-02-09 07:07

Review time: 4 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors reviewed all previous case reports about EGFR-Tkis in NSCLC patients Undergoing HD 。It was mentioned that since the main metabolic pathway of EGFR-Tkis is through the liver, and the plasma protein binding rate of EGFR-Tkis is very high, there is no need to adjust the dose after HD. Therefore, EGFR-Tkis are effective and well tolerated in HD patients.It provides a good direction for the selection of clinical medication, and I suggest that this article can be accepted.However, I am not an expert in pharmacokinetics, please refer to the opinions of other experts for relevant content.Thank you for inviting!

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 75312

Title: Review EGFR-TKIs administration to non-small-cell lung cancer patients undergoing hemodialysis

Provenance and peer review: Unsolicited manuscript; externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02818262
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: France

Author's Country/Territory: Taiwan

Manuscript submission date: 2022-01-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-03-06 21:13

Reviewer performed review: 2022-03-06 21:50

Review time: 1 Hour

Scientific quality	[Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This well written and extensive narrative review of case reports on hemodialysis patients with metastatic lung cancer in most treated by the different oral Epidermal Growth Factor receptor (EGFR)-Tyrosine Kinase inhibitors (TKIs)is of high interest owing to the lack of clinical trial of EGFR-TKIs in end-stage kidney disease (ESKD). It shows in details the efficiency of these molecules together with their good tolerance in ESKD. This review is in the scope of the Journal and of high scientific interest owing the the usual contraindication of classical chemotherapy in dialysis setting. Two specific comments: in the introduction paragraph, I would add that cancer frequency "in general" (not only lung cancer) is highly increased in dialysis patients. Concerning Cisplatin, I would also add that there is an important risk of bone marrow aplasia in ESKD.